Physician profile
Mark Lebehn
NPI 1437444643
$8,875.59
in general payments reported to CMS, 2019-2025
16 companies · $2,335 in 2025
The $2,335 reported for 2025 was more than what 86% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2020: $209 · 2021: $1,574 · 2022: $1,848 · 2023: $866 · 2024: $1,688 · 2025: $2,335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,077 · Travel and Lodging: $1,812.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,076.71 |
| Travel and Lodging | $1,811.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,179.56 | 2020-2025 | Portico, Triclip, Mitraclip |
| Edwards Lifesciences Corporation | $2,429.03 | 2020-2025 | Sapien 3 Ultra Resilia, Pascal |
| Medtronic, INC. | $1,102.02 | 2022-2025 | Corevalve Evolut R |
| Boston Scientific Corporation | $644.68 | 2019-2024 | Watchman Flx |
| Janssen Pharmaceuticals, INC | $274.95 | 2021-2023 | Xarelto |
| Angiodynamics, INC. | $254.31 | 2023 | Alphavac |
| Abiomed | $240.52 | 2021 | |
| Philips North America LLC | $142.08 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $131.00 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $125.06 | 2020-2023 | Lifevest |
| Biotronik INC. | $120.58 | 2019 | |
| W. L. Gore & Associates, INC. | $99.95 | 2019 | |
| Ge Healthcare | $50.07 | 2025 | |
| Amarin Pharma, INC. | $36.77 | 2021 | |
| Teleflex LLC | $28.78 | 2025 | Guideliner |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lantheus Medical Imaging, INC. | $16.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Lebehn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.